A Phase 3 interventional study of Atezolizumab and Bevacizumab in Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 80 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive atezolizumab by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Drug: Atezolizumab
Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Drug: Atezolizumab · Drug: Bevacizumab · Drug: Alectinib · Drug: Cobimetinib · Drug: Vemurafenib · Drug: FAP IL2V · Drug: Venetoclax · Drug: Enzalutamide · Drug: Niraparib · Drug: Cabozantinib · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Emactuzumab · Drug: Rucaparib
Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Drug: Cobimetinib · Drug: Vemurafenib · Drug: Venetoclax · Drug: Enzalutamide · Drug: Pembrolizumab · Drug: Sunitinib · Drug: Niraparib · Drug: Pemetrexed · Drug: Paclitaxel
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Also known as: Tecentriq
Bevacizumab will be administered as directed per the parent study.
Also known as: Avastin
Alectinib will be administered as directed per the parent study.
Also known as: Alecensa
Cobimetinib will be administered as directed per the parent study.
Also known as: Cotellic
Vemurafenib will be administered as directed per the parent study.
Also known as: Zelboraf
FAP IL2V will be administered as directed per the parent study.
Also known as: simlukafusp alfa
Venetoclax will be administered as directed per the parent study.
Also known as: Venclexta
Enzalutamide will be administered as directed per the parent study.
Also known as: Xtandi
Pembrolizumab will be administered as directed per the parent study.
Also known as: Keytruda
Sunitinib will be administered as directed per the parent study.
Also known as: Sutent
Niraparib will be administered as directed per the parent study.
Also known as: Zejula
Cabozantinib will be administered as directed per the parent study.
Also known as: Cometriq
Pemetrexed will be administered as directed per the parent study.
Paclitaxel will be administered as directed per the parent study.
Emactuzumab will be administered as directed per the parent study.
Rucaparib will be administered as directed per the parent study.
Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)
Time frame: Day 1 up to maximum 10 years
Percentage of Participants With Serious Adverse Events (SAEs) According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Time frame: Day 1 up to 90 days after last dose of study treatment (last dose=until clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Percentage of Participants With Adverse Events of Special Interest Determined According to NCI CTCAE Version 5.0
Time frame: Day 1 up to 90 days after last dose of study treatment (last dose=until clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Treatment Duration
Time frame: Day 1 up to 90 days after last dose of study treatment (last dose=until clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Total Dose Received
Time frame: Day 1 up to 90 days after last dose of study treatment (last dose=until clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Number of Treatment Cycles
Time frame: Day 1 up to 90 days after last dose of study treatment (last dose=until clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche